Support Care Cancer DOI 10.1007/s00520-014-2187-2
ORIGINAL ARTICLE
Use of and spending on supportive care medications among Medicare beneficiaries with cancer Ilene H. Zuckerman & Amy J. Davidoff & Mujde Z. Erten & Bruce Stuart & Thomas Shaffer & J. Samantha Dougherty & Candice Yong
Received: 4 December 2013 / Accepted: 2 March 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose The study objective was to provide population-based estimates of supportive care medication (SCM) use among Medicare beneficiaries with cancer and determine factors related to SCM receipt. Methods This retrospective cohort study of community-based Medicare beneficiaries used the Medicare Current Beneficiary Survey (1997–2007). Dependent variables comprised use and spending on SCMs for three medication classes: opioids, antidepressants/sedative/hypnotics (ASH), and antiemetics. Independent variables of interest were supplemental insurance coverage, cancer site, and treatment. Multivariate models determined factors affecting receipt of, and spending on, SCMs. We also compared SCM use and spending among beneficiaries with and without cancer in order to understand Electronic supplementary material The online version of this article (doi:10.1007/s00520-014-2187-2) contains supplementary material, which is available to authorized users. I. H. Zuckerman : A. J. Davidoff : B. Stuart : T. Shaffer : J. S. Dougherty : C. Yong Peter Lamy Center on Drug Therapy and Aging, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA
what portion of SCM use and spending could be attributed to cancer as opposed to other comorbid conditions. Results A total of 1,836 Medicare beneficiaries with cancer and 9,898 beneficiaries without cancer were eligible for the study. Beneficiaries with cancer were more likely to receive opioids, ASH, and antiemetics compared to non-cancer beneficiaries. Adjusted annual payments for antiemetics were on average $637 higher in with cancer versus without cancer (p
ORIGINAL ARTICLE
Use of and spending on supportive care medications among Medicare beneficiaries with cancer Ilene H. Zuckerman & Amy J. Davidoff & Mujde Z. Erten & Bruce Stuart & Thomas Shaffer & J. Samantha Dougherty & Candice Yong
Received: 4 December 2013 / Accepted: 2 March 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Purpose The study objective was to provide population-based estimates of supportive care medication (SCM) use among Medicare beneficiaries with cancer and determine factors related to SCM receipt. Methods This retrospective cohort study of community-based Medicare beneficiaries used the Medicare Current Beneficiary Survey (1997–2007). Dependent variables comprised use and spending on SCMs for three medication classes: opioids, antidepressants/sedative/hypnotics (ASH), and antiemetics. Independent variables of interest were supplemental insurance coverage, cancer site, and treatment. Multivariate models determined factors affecting receipt of, and spending on, SCMs. We also compared SCM use and spending among beneficiaries with and without cancer in order to understand Electronic supplementary material The online version of this article (doi:10.1007/s00520-014-2187-2) contains supplementary material, which is available to authorized users. I. H. Zuckerman : A. J. Davidoff : B. Stuart : T. Shaffer : J. S. Dougherty : C. Yong Peter Lamy Center on Drug Therapy and Aging, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA
what portion of SCM use and spending could be attributed to cancer as opposed to other comorbid conditions. Results A total of 1,836 Medicare beneficiaries with cancer and 9,898 beneficiaries without cancer were eligible for the study. Beneficiaries with cancer were more likely to receive opioids, ASH, and antiemetics compared to non-cancer beneficiaries. Adjusted annual payments for antiemetics were on average $637 higher in with cancer versus without cancer (p
